including atopic dermatitis (AD), in which it is considered the gold standard, says pharma analytics company GlobalData. Filippos Maniatis, healthcare analyst at GlobalData, commented: “Having ...

On May 26, 2020, Sanofi Consumer Health achieved FDA approval for Dupixent, a biologic medicine for children suffering from moderate to severe atopic dermatitis and between the age group of 6 and 11 ...

‘The #atopic_dermatitis market is heating up! #Sanofi is gearing up to challenge #Dupixent's dominance. What new treatments are on the horizon?’ Sanofi is also advancing in the AD arena with ...

including atopic dermatitis (AD), in which it is considered the gold standard, says GlobalData, a data and analytics company. “Having Dupixent as the gold standard for AD, Sanofi has set a high ...

This achievement further emphasises the drug’s efficacy across multiple indications, including atopic dermatitis (AD), in which it is considered the gold standard. The use of Dupixent in AD has ...

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

AD, The most common inflammatory skin disorder worldwide, is a highly heterogeneous condition with current treatments that do not address the multiple inflammatory pathways that cause its specific ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

Data from a retrospective multicenter study, along with a review of previous trials, supported the real-world utility of ...

Dupixent (dupilumab) was the first biologic medicine to get approval for atopic dermatitis in 2017, and since then has grown sales to more than $2 billion last year, with Sanofi suggesting it ...

Pfizer could be just a few months away from getting FDA approval for its JAK1 inhibitor abrocitinib in atopic dermatitis ... like Sanofi and Regeneron’s Dupixent (dupilumab), which dominates ...